Oncostatin M reverses ABCG2-mediated mitoxantrone resistance

被引：0

作者：

Blauz, Andrzej ^{[1
]}

Wachulec, Marcin ^{[1
]}

Rychlik, Blazej ^{[1
]}

机构：

[1] Univ Lodz, Fac Biol & Environm Protect, Dept Oncobiol & Epigenet, Cytometry Lab, Lodz, Poland

来源：

BIOMEDICINE & PHARMACOTHERAPY | 2024年 / 176卷

关键词：

Oncostatin M mitoxantrone Multidrug; resistance; MULTIDRUG-RESISTANCE; PROTEIN BCRP/ABCG2; TRANSPORTER; EXPRESSION; HOECHST-33342;

D O I：

10.1016/j.biopha.2024.116861

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Mitoxantrone resistant variant of SW620 line was developed, characterized and subsequently used as a model system to determine oncostatin M ability to modulate MDR phenomenon. The selection regimen allowed for overexpression of ABCG2 and ABCB1 both at the RNA and protein level, which was further confirmed by functional assays. Oncostatin M supplementation resulted in partial reversal of MDR phenotype by decreasing overexpression of ABCG2 demonstrating for the first time the ability of this cytokine for selective downregulation of one of MDR proteins.

引用

页数：7

共 50 条

[31] Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance
Wu, Zhuo-Xun
Yang, Yuqi
Teng, Qiu-Xu
Wang, Jing-Quan
Lei, Zi-Ning
Wang, Jing-Qiu
Lusvarghi, Sabrina
Ambudkar, Suresh V.
Yang, Dong-Hua
Chen, Zhe-Sheng
CANCERS, 2020, 12 (01)
[32] Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance
Nakamura, Y
Oka, M
Soda, H
Shiozawa, K
Yoshikawa, M
Itoh, A
Ikegami, Y
Tsurutani, J
Nakatomi, K
Kitazaki, T
Doi, S
Yoshida, H
Kohno, S
CANCER RESEARCH, 2005, 65 (04) : 1541 - 1546
[33] Tumor-acquired somatic mutation affects conformation to abolish ABCG2-mediated drug resistance
Gose, Tomoka
Rasouli, Ali
Dehghani-Ghahnaviyeh, Sepehr
Wen, Po-Chao
Wang, Yao
Lynch, John
Fukuda, Yu
Shafi, Talha
Ford, Robert C.
Tajkhorshid, Emad
Schuetz, John D.
DRUG RESISTANCE UPDATES, 2024, 73
[34] SIS3, a specific inhibitor of Smad3 reverses ABCB1-and ABCG2-mediated multidrug resistance in cancer cell lines
Wu, Chung-Pu
Murakami, Megumi
Hsiao, Sung-Han
Liu, Te-Chun
Yeh, Ni
Li, Yan-Qing
Hung, Tai-Ho
Wu, Yu-Shan
Ambudkar, Suresh V.
CANCER LETTERS, 2018, 433 : 259 - 272
[35] ABCG2-mediated transport of photosensitizers - Potential impact on photodynamic therapy
Robey, RW
Steadman, K
Polgar, O
Bates, SE
CANCER BIOLOGY & THERAPY, 2005, 4 (02) : 187 - 194
[36] Bisindolylmaleimide and indolocarbazole protein kinase (PK) inhibitors reverse ABCG2-mediated drug transport and resistance
Robey, Robert W.
Shukla, Suneet
Steadman, Kenneth
Ambudkar, Suresh V.
Bates, Susan E.
CANCER RESEARCH, 2006, 66 (08)
[37] Differential interaction of enterolignans with the ovine ABCG2-mediated transport of danofloxacin
Merino, G.
Garcia-Mateos, D.
Otero, J. A.
Olazabal-Moran, M.
Garcia-Lino, A. M.
Alvarez, A. I.
JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2018, 41 : 140 - 140
[38] A Novel Two Mode-Acting Inhibitor of ABCG2-Mediated Multidrug Transport and Resistance in Cancer Chemotherapy
Peng, Hui
Dong, Zizheng
Qi, Jing
Yang, Youyun
Liu, Yang
Li, Zhaomin
Xu, Junkang
Zhang, Jian-Ting
PLOS ONE, 2009, 4 (05):
[39] A novel two mode-acting inhibitor of ABCG2-mediated multidrug transport and resistance in cancer chemotherapy
Peng, Hui
Dong, Zizheng
Qi, Jing
Yang, Youyun
Liu, Yang
Li, Zhaomin
Xu, Junkang
Zhang, Jian-Ting
CANCER RESEARCH, 2009, 69
[40] Enhanced reversal of ABCG2-mediated drug resistance by replacing a phenyl ring in baicalein with a meta-carborane
Kuhnert, Lydia
Kuhnert, Robert
Sarosi, Menyhart B.
Lakoma, Cathleen
Scholz, Birte K.
Loennecke, Peter
Hey-Hawkins, Evamarie
Honscha, Walther
MOLECULAR ONCOLOGY, 2024, 18 (02) : 280 - 290

← 1 2 3 4 5 →